Literature DB >> 9535149

Insulin resistance in essential hypertension is characterized by impaired insulin stimulation of blood flow in skeletal muscle.

H Laine1, M J Knuuti, U Ruotsalainen, M Raitakari, H Iida, J Kapanen, O Kirvelä, M Haaparanta, H Yki-Järvinen, P Nuutila.   

Abstract

OBJECTIVE: To determine whether insulin-stimulated blood flow in patients with mild essential hypertension is altered.
SUBJECTS: Eleven untreated mildly hypertensive patients [aged 35 +/- 2 years, body mass index 25.1 +/- 0.4 kg/m2, mean arterial pressure 110 +/- 2 mmHg (means +/- SEM) and 10 matched normotensive subjects (mean arterial pressure 94 +/- 3 mmHg).
METHODS: Blood flow was quantitated directly in skeletal muscle both basally and during supraphysiologic hyperinsulinemia (serum insulin approximately = 450 mU/l) using radiowater ([15O]H2O) and positron emission tomography. Whole-body and femoral muscle glucose uptakes were determined using the euglycemic insulin clamp technique, [18F]-2-fluoro-2-deoxy-D-glucose and positron emission tomography.
RESULTS: Rates of whole-body and femoral muscle glucose uptake were significantly lower in the hypertensive than in the normotensive group. Insulin increased muscle blood flow by 91% in the normotensive group, but only by 33% in the hypertensive group.
CONCLUSIONS: The ability of insulin to stimulate blood flow in patients with mild essential hypertension is impaired.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9535149     DOI: 10.1097/00004872-199816020-00012

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  2 in total

1.  Regulation of muscle microcirculation in health and diabetes.

Authors:  Zhenqi Liu; Seung-Hyun Ko; Weidong Chai; Wenhong Cao
Journal:  Diabetes Metab J       Date:  2012-04-17       Impact factor: 5.376

2.  Metabolic syndrome, chronic kidney disease, and cardiovascular disease: a dynamic and life-threatening triad.

Authors:  Mário Raimundo; José António Lopes
Journal:  Cardiol Res Pract       Date:  2011-02-20       Impact factor: 1.866

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.